Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PODOMOUNT-Basket Phase II Trial of BI 764198 in Proteinuric Kidney Diseases
jRCT2031250808Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in proteinuric kidney disease, nephrosis and Podocytopathies comparing BI 764198 with Placebo (2 arms). Primary endpoint: Relative change in 24-hour urine protein-to-creatinine ratio. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
apecotrep
03
Conditions
proteinuric kidney diseasenephrosisPodocytopathies
Beyond the preview
Go deeper on jRCT2031250808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250808.